Oireachtas Health Committee report on Orphan Drugs welcomed by the pharmaceutical industry
Posted on March, 06 - 2018
The Irish Pharmaceutical Healthcare Association (IPHA), which represents 47 research based pharmaceutical companies in Ireland has welcomed the publication of a report on Evaluating Orphan Drugs which has been published by the Joint Oireachtas Committee on Health.
Commenting on the publication, IPHA CEO, Oliver O’Connor said: “The Joint Committee on Health under the chairmanship of Dr Michael Harty has done a very thorough job. IPHA has been highlighting for some time that patients in Ireland are not getting access to new drugs, including orphan drugs as fast as in other European countries. The report recognises this and the importance of making new orphan drugs available to patients as quickly as possible
IPHA especially welcomes the recommendations that the process for assessment of orphan drugs should be amended and that there should be clinician and patient involvement in this process. The establishment of a specific budget for orphan drugs would also be a very positive development.
IPHA companies are deeply committed to ensuring the best and most innovative medicines get to patients in Ireland as fast as in other European countries. IPHA will engage proactively in this agenda with the Oireachtas and stakeholders mentioned in the report.
Contact Philip Hannon on 087 2870891